...
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >A novel dominant B-cell epitope of FSHR identified by molecular docking induced specific immune response and suppressed fertility.
【24h】

A novel dominant B-cell epitope of FSHR identified by molecular docking induced specific immune response and suppressed fertility.

机译:通过分子对接鉴定的FSHR的新型显性B细胞表位诱导特异性免疫应答并抑制生育力。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The follicle stimulating hormone (FSH) is of great importance in reproduction modulation of both sexes. The extracellular domain (ECD) of its receptor (FSHR) is crucial for FSH binding and subsequent signal transduction; therefore, it is the potential target for fertility control. To avoid unwanted side-effect when used as immunocontraceptive agent, the ECD was analysed by online prediction combined with molecular docking to identify the candidate B-cell epitopes. Four potential B-cell epitopes were identified and synthesised in tandem with Pan DR epitope. Then the epitope-based peptides were used to boost adult male mice following rhFSHR protein priming, thus to determine their immune responses and fertility inhibition capacity. Three of the four peptides showed suppressed fertility accompanied with small testis and lower serum testosterone level, which was consistent with absolutely lower sperm quantity and poor quality. Among the four epitope peptides, Pep2 displayed the lowest fertility rate of 26.67%, which was similar to that of rhFSHR homologously prime/boost mice (23.30 and 25.00%). Thus, we identified a novel immunodominant B-cell epitope by molecular docking and protein prime/peptide boost strategy.
机译:卵泡刺激素(FSH)在男女生殖调节中都非常重要。受体(FSHR)的细胞外结构域(ECD)对于FSH结合和随后的信号转导至关重要。因此,这是控制生育的潜在目标。为了避免在用作免疫避孕药时产生不良副作用,通过在线预测结合分子对接分析了ECD,以鉴定候选B细胞表位。鉴定了四个潜在的B细胞表位,并与Pan DR表位串联合成。然后,基于表位的肽在rhFSHR蛋白启动后用于增强成年雄性小鼠,从而确定其免疫应答和抑制生育能力。四种肽中的三种显示出受精性受抑制,伴有睾丸小和血清睾丸激素水平降低,这与精子数量绝对减少和质量差相一致。在这四个表位肽中,Pep2的受精率最低,为26.67%,与rhFSHR同源的初免/加强型小鼠相似(23.30和25.00%)。因此,我们通过分子对接和蛋白质初免/肽加强策略确定了一种新型的免疫优势B细胞表位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号